Corvus Pharmaceuticals, Inc. (CRVS) vs SpyGlass Pharma, Inc. Common Stock (SGP)
A side-by-side comparison of Corvus Pharmaceuticals, Inc. and SpyGlass Pharma, Inc. Common Stock across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
CRVS
Corvus Pharmaceuticals, Inc.
$10.56HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
SGP
SpyGlass Pharma, Inc. Common Stock
$24.78HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — CRVS vs SGP
growth of $100 · dividends reinvested · last 1yCRVS -48.4% (-48.4%/yr)SGP -3.1% (-3.1%/yr)SGP compounded faster over this window
CRVS SGP
CRVS vs SGP: by the numbers
- •CRVS is the larger company ($888M vs $828M market cap).
Metrics side by side
Valuation
| Metric | CRVS | SGP |
|---|---|---|
| P/B ratio | 3.94 | 3.57 |
Profitability
| Metric | CRVS | SGP |
|---|---|---|
| Gross margin | 0.00% | 0.00% |
| Operating margin | 0.00% | 0.00% |
| Net margin | 0.00% | 0.00% |
| ROE | -24.02% | -24.12% |
| ROIC | -25.25% | -26.54% |
Growth (annualized)
| Metric | CRVS | SGP |
|---|---|---|
| Total return CAGR (5Y) | 17.88% | N/A |
Go deeper
Dig into the metrics
Corvus Pharmaceuticals ROESpyGlass Pharma, Inc. Common Stock ROECorvus Pharmaceuticals operating marginSpyGlass Pharma, Inc. Common Stock operating marginCorvus Pharmaceuticals revenue growthSpyGlass Pharma, Inc. Common Stock revenue growthCorvus Pharmaceuticals free cash flowSpyGlass Pharma, Inc. Common Stock free cash flow
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.